CMR FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwebke, J. R.
Right arrow Articles by Burgess, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwebke, J. R.
Right arrow Articles by Burgess, D.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, October 2004, p. 794-803, Vol. 17, No. 4
0893-8512/04/$08.00+0     DOI: 10.1128/CMR.17.4.794-803.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Trichomoniasis

Jane R. Schwebke1* and Donald Burgess2

Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama,1 Department of Protistology, American Type Culture Collection, Manassas, Virginia2

Trichomoniasis is perhaps the most common curable sexually transmitted disease worldwide, yet few resources are devoted to its control. It is associated with potentially serious complications such as preterm birth and human immunodeficiency virus acquisition and transmission. The immunology of a related organism, Tritrichomonas foetus, which causes disease in cattle, has been investigated to some extent, but more work is needed for the human strain, Trichomonas vaginalis. In addition, although trichomoniasis is easily treated with oral metronidazole, there is concern that the number of strains resistant to this antibiotic are increasing, and currently no alternative is licensed in the United States. As more is appreciated concerning the important public health implications of this common infection, more work will need to be done in understanding the diagnosis, treatment, and immunology of this organism.


* Corresponding author. Mailing address: Department of Medicine, Division of Infectious Diseases, 703 19th St. South, Zeigler Research Bldg. no. 239, Birmingham, AL 35294-0007. Phone: (205) 975-5665. Fax: (205) 975-7764. E-mail: Schwebke{at}uab.edu.


Clinical Microbiology Reviews, October 2004, p. 794-803, Vol. 17, No. 4
0893-8512/04/$08.00+0     DOI: 10.1128/CMR.17.4.794-803.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Vaccine Immunol.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.